Mirum Pharmaceuticals, Inc. (MIRM)
MIRMNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$93.18
-0.5400 (-0.58%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $6.08bn
- P/E
- –
- EPS, last 4 quarters
- $-2.17
- Dividend yield
- –
- Day range
- –
- 52-week range
- $63.23 to $130.00
- Average volume
- 720.1k
- Previous close
- $93.72
Analysts
12 coveringBuy12 buy, 0 hold, 0 sell
Targets a year out average $157.91, +69.5% from here
Earnings
next estimate $-0.6700Next report
Dec 2025
-650.0%
Mar 2026
+2.5%
Jun 2026
-3.9%
Sep 2026
-64.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $148.93m | $159.88m | $176.24m | $185.72m |
| Gross profit | $120.67m | $131.08m | $145.90m | $150.55m |
| Operating income | -$4.57m | -$789.47m | -$42.54m | -$59.75m |
| Net income | -$5.73m | -$790.15m | -$67.23m | -$40.77m |
Last four quarters: revenue $670.78m, margin -134.8%, free cash flow -$273.85m
News
8 latest- Mirum (MIRM) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- Mirum Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- Mirum Pharmaceuticals Reports Q3 2026 Financial Results and Raises Full-Year Sales GuidanceFintel · 6 days ago
- Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 EarningsZacks · 6 days ago
- Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue EstimatesZacks · 6 days ago
- Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks · Oct 28, 2026
- Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks · Oct 27, 2026
- Mirum's ATEBRIOZ Reduces Bone Lesion Volume In Younger Children With FOP; Stock Up RTTNews · Oct 26, 2026
The company
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company's commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), ATEBRIOZ (zilurgisertib) for fibrodysplasia ossificans progressiva (FOP), CHOLBAM (cholic acid) for bile-acid synthesis disorders and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- mirumpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.